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Photodynamic therapy (PDT) is widely used for the treatment of skin cancer. Mechanistically, in 
delta−aminolevulinic acid (ALA)−mediated PDT, the addition of ALA to cells bypasses the 
negative feedback control of heme biosynthesis, leading to accumulation of photosensitizing 
concentrations of protoporphyrin IX (PPIX). Subsequent activation of cellular PPIX with an 
external light source (usually red light, 550−750nm) leads to generation of reactive oxygen 
species, resulting in cell death. The major side effect of ALA−PDT treatment is the pain 
experienced by patients. Management of treatment−related pain still remains a considerable 
challenge in patients. Further optimization of the treatment protocol including light source, dose 
and duration therefore seems crucial to try and address this issue. To improve the efficiency of 
ALA−PDT of skin cells: (i) we changed the conventional light source to UVA (320−400 nm) that is 
absorbed more efficiently by PPIX and is 40−fold more potent in killing cultured skin cells than red 
light [1]; (ii) we combined ALA treatment with the potent iron chelators, salicylaldehyde 
isonicotinoyl hydrazone (SIH), pyridoxal isonicotinoyl hydrazone (PIH) or desferrioxamine (DFO) 
to further increase the accumulation of PPIX through the depletion of iron available for 
ferrochelatase−mediated bioconversion of PPIX to heme. Spontaneously immortalised HaCaT 
keratinocytes were pre−treated (or not) for 18h with SIH, PIH or DFO (20−100 uM), then 
subjected to ALA (0.5 mM) for 2h and irradiated with low doses of UVA (5−50 kJ/m2). The 
quantification of intracellular PPIX was carried out by both HPLC and spectrofluorimtery after 
treatments of cells with ALA alone or combined with chelators. Cell death was examined 24h after 
UVA exposure of ALA+/−chelators−treated cells by flow cytometry using Annexin V−propidium 
iodide dual staining assay. Pretreatment of HaCaT cells with ALA caused a substantial increase 
in the intracellular levels of PPIX which in turn sensitized the cells to very low non−cytotoxic UVA 
doses. Pre−treatment with DFO, PIH and SIH followed by ALA treatment further enhanced the 
PPIX level in HaCaT cells and caused an additional level of photosensitization to low UVA doses. 
Among the chelators used, SIH combined with ALA provided the most efficient increase in PPIX 
and cell killing following UVA irradiation, even at a lower SIH concentration of 20 uM. UVA−based 
ALA−PDT combined with SIH appears therefore to be a promising modality for topical PDT. The 
high lipophilicity of SIH which facilitates skin penetration and its potent cytotoxicity at low UVA 
doses should therefore allow the current modality for topical PDT to be improved, through a 
reduction of the time of irradiation and therefore the duration of pain experienced through the 
treatment.  
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